Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Other Accumulated Expenses (2021 - 2026)

Champions Oncology has reported Other Accumulated Expenses over the past 6 years, most recently at $78000.0 for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses fell 49.35% year-over-year to $78000.0; the TTM value through Jan 2026 reached $78000.0, down 49.35%, while the annual FY2025 figure was $135000.0, 10.0% down from the prior year.
  • Other Accumulated Expenses for Q1 2026 was $78000.0 at Champions Oncology, down from $97000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $154000.0 in Q1 2025 and troughed at $15000.0 in Q1 2022.
  • A 5-year average of $125647.1 and a median of $144000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: surged 860.0% in 2023 and later crashed 49.35% in 2026.
  • Year by year, Other Accumulated Expenses stood at $143000.0 in 2022, then rose by 3.5% to $148000.0 in 2023, then rose by 2.03% to $151000.0 in 2024, then plummeted by 35.76% to $97000.0 in 2025, then fell by 19.59% to $78000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for CSBR at $78000.0 in Q1 2026, $97000.0 in Q4 2025, and $116000.0 in Q3 2025.